Skip to main content

Advertisement

Fig. 3 | Cell & Bioscience

Fig. 3

From: Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus

Fig. 3

Analysis of E7-antigen-specific immune response generated by pcDNA3-BPVL1-E7(49-57) vaccination. a Schema of experiment. Briefly, 6–8 week old female C57BL/6 mice (5 per group) were vaccinated IM with (1) 20 μg of empty pcDNA3 vector, (2) 10 μg of pcDNA3-E7(49-57) + 10 μg of empty pcDNA3 vector, (3) 10 μg of pcDNA3-BPVL1 + 10 μg of pcDNA3-E7(49-57), or (4) 10 μg of pcDNA3-BPVL1-E7(49-57) + 10 μg of empty pcDNA3 vector, followed by electroporation on day 1. Mice were boosted with the same regimen on day 7. b, c Seven days after the last vaccination, splenocytes from the mice were collected and stimulated with HPV16 E7aa49-57 peptide in the presence of GolgiPlug, stained for surface CD8 and intracellular IFN-γ, and analyzed using flow cytometry. b Representative flow cytometry image for the amount of IFNγ + CD8+ T cells among splenocytes. c Bar graph summary of flow cytometry analysis

Back to article page